BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.

70.54
EUR
0.00
(0.00%)
-2.61EPS
11.45BMarket Cap
Feb 25Next Earn

Total Valuation

EUR

As of September 30, 2026, BridgeBio Pharma, Inc. carries a market capitalization of 11.45B, placing it among publicly traded companies globally. Its enterprise value stands at 13.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap11.45B
Enterprise Value13.14B

Important Dates

BridgeBio Pharma, Inc.'s next confirmed earnings release is scheduled for February 25, 2027.

Earnings Date2/25/2027

Share Statistics

As of September 30, 2026, BridgeBio Pharma, Inc. has 196.00M shares outstanding.

Shares Outstanding196.00M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 13.66, and the price-to-book ratio stands at -4.98.

PS Ratio13.66
PB Ratio-4.98
P/TBV Ratio-4.93
P/FCF Ratio-34.93
P/OCF Ratio-35.01

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 15.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.14B versus a market cap of 11.45B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales15.75

Financial Position

As of September 30, 2026, BridgeBio Pharma, Inc. maintains a current ratio of 2.09, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -150.83, indicating conservative leverage, while an interest coverage ratio of -1.69 demonstrates limited ability to service its debt obligations.

Current Ratio2.09
Quick Ratio1.96
Debt / Equity-150.83
Debt / EBITDA-6.94
Interest Coverage-1.69

Financial Efficiency

EUR

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -35.81, reflecting losses generated across the asset base. The company generates approximately 994,338.43 in revenue per employee across its workforce of 839.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.27 indicates how many times BridgeBio Pharma, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-35.81
Revenue Per Employee994,338.43
Employee Count839.00
Inventory Turnover1.27

Taxes

EUR

Over the twelve months ended September 30, 2026, BridgeBio Pharma, Inc. recorded 978,470.70 in income tax expense. The company reported a pretax loss of -508.62M and -499.23M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax978,470.70

Stock Price Statistics

EUR

As of the close on November 17, 2026, BridgeBio Pharma, Inc.'s stock has gained approximately 22.85% over the past 52 weeks. The 50-day moving average sits at 62.21, while the 200-day moving average is 63.13.

52-Week Price Change22.85%
50-Day Moving Average62.21
200-Day Moving Average63.13

Income Statement

EUR

Over the twelve months ended September 30, 2026, BridgeBio Pharma, Inc. generated 834.25M in revenue and converted that into -499.23M in net income, yielding earnings per share of -2.61. EBITDA reached -317.18M, while operating income came in at -311.54M.

Revenue834.25M
Gross Profit787.01M
Operating Income-311.54M
Pretax Income-508.62M
Net Income-499.23M
EBITDA-317.18M
EBIT-321.37M
Earnings Per Share (EPS)-2.61

Balance Sheet

EUR

As of September 30, 2026, BridgeBio Pharma, Inc. holds 1.36B in cash and equivalents against 2.20B in total debt, resulting in a net debt position of 832.94M. Total book value stands at -2.30B, with working capital of 941.74M providing operational flexibility.

Cash & Cash Equivalents1.36B
Total Debt2.20B
Net Debt832.94M
Equity (Book Value)-2.30B
Book Value Per Share-11.73
Working Capital941.74M

Cash Flow

EUR

BridgeBio Pharma, Inc. produced -325.54M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -736,720.50 in capital expenditures, free cash flow totaled -326.28M - equivalent to -1.67 per share.

Operating Cash Flow-325.54M
Capital Expenditures-736,720.50
Free Cash Flow-326.28M
FCF Per Share-1.67

Margins

Over the twelve months ended September 30, 2026, BridgeBio Pharma, Inc. posted a gross margin of 94.34, reflecting its pricing power and cost economics. The operating margin of -37.34 and net profit margin of -59.84 provide insight into operational efficiency.

Gross Margin94.34
Operating Margin-37.34
Pretax Margin-60.97
Profit Margin-59.84
EBITDA Margin-38.02

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. The dividend payout ratio of 4.27 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -2.86: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -9.72, meaning BridgeBio Pharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Payout Ratio4.27
Shareholder Yield-9.72
FCF Yield-2.86

Scores

As of September 30, 2026, BridgeBio Pharma, Inc. has an Altman Z-Score of -0.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.21